title: Mixed genotype hepatitis C infections and implications for treatment.
authors.affiliation: MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.
authors.forename: Anna L
authors.initials: AL
authors.lastname: McNaughton
authors.forename: Emma C
authors.initials: EC
authors.lastname: Thomson
authors.forename: Kate
authors.initials: K
authors.lastname: Templeton
authors.forename: Rory N
authors.initials: RN
authors.lastname: Gunson
authors.forename: E Carol McWilliam
authors.initials: EC
authors.lastname: Leitch
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics*; D005838:Genotype; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D015995:Prevalence; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline